STOCK TITAN

Relay Therapeutics (RLAY) SEC Filings, Jul-Oct 2025

RLAY NASDAQ

Relay Therapeutics, Inc. filings document the regulatory record of a clinical-stage precision-medicine company developing small molecule programs for cancer and genetic disease. Form 8-K reports include operating and financial results, Regulation FD clinical updates for zovegalisib, FDA Breakthrough Therapy designation disclosure, material agreements, capital-structure matters, and governance changes.

Proxy materials describe board composition, committee structure, executive compensation, equity awards, shareholder voting matters, and related governance policies. Other filings address amendments to bylaws, including exclusive-forum provisions, and securities disclosures tied to RLAY common stock and its development-stage pipeline.

Rhea-AI Summary

Relay Therapeutics (RLAY) insider transaction: The Chief Corporate Development Officer reported sales of common stock primarily to cover taxes from recent RSU vesting. On October 28, 2025, 19,135 shares were sold at $7.29. On October 29, 2025, 21,394 shares were sold at a weighted average price of $7.50, with trade prices ranging from $7.49 to $7.52.

The sale on October 28, 2025 was to satisfy income tax withholding upon the vesting of 47,897 RSUs on October 27, 2025, and the reporting person had no discretion over that transaction. Following these sales, the reporting person beneficially owns 337,469 shares, which include 108,919 shares underlying RSUs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.72%
Tags
insider
-
Rhea-AI Summary

Relay Therapeutics (RLAY) reported an insider transaction by its Chief Financial Officer. The CFO sold 21,664 shares of common stock at $7.29 on October 28, 2025. The filing states the sale was to cover income tax withholding tied to the vesting of 48,115 RSUs on October 27, 2025, and the officer had no discretion over the sale under company policy. Following the transaction, the officer beneficially owned 313,631 shares, which includes 110,008 shares underlying RSUs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.72%
Tags
insider
-
Rhea-AI Summary

Relay Therapeutics (RLAY) officer reports Form 4 transaction. On 10/28/2025, the President, R&D sold 30,897 shares of common stock at $7.29 per share. The filing states the sale was made to cover income tax withholding obligations tied to the vesting of 68,622 RSUs on October 27, 2025, and the reporting person had no discretion over the transaction under company policies.

Following the transaction, the officer beneficially owned 521,823 shares, held directly. This total includes 168,866 shares underlying RSUs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.72%
Tags
insider
Schedule 13G/A
Rhea-AI Summary

Commodore Capital and related filers reported beneficial ownership of 13,350,000 shares of Relay Therapeutics (RLAY), representing 7.8% of the outstanding common stock as of June 30, 2025. The Schedule 13G/A names Commodore Capital LP, Commodore Capital Master LP, and managing partners Michael Kramarz and Robert Egen Atkinson as joint filers. The Firm acts as investment manager to Commodore Capital Master LP and the managing partners exercise investment discretion. The filing states the position was not acquired to change or influence control and attaches a Joint Filing Agreement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.42%
Tags
other
-
Rhea-AI Summary

Point72-related filers reported a 7.8% stake in Relay Therapeutics (RLAY). The Schedule 13G/A shows Point72 Asset Management, Point72 Capital Advisors and Steven A. Cohen collectively report shared voting and dispositive power over 13,445,704 shares of Relay common stock as of the close of business on June 30, 2025. The shares are held through Point72 Associates, an investment fund managed by Point72 Asset Management, and Cubist Systematic Strategies, LLC acted as a sub-advisor for a portion of the holdings. The filing includes a certification that the position was not acquired to influence control of the issuer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.42%
Tags
other
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.74%
Tags
current report
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
insider
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
insider
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
insider
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
insider

FAQ

How many Relay Therapeutics (RLAY) SEC filings are available on StockTitan?

StockTitan tracks 114 SEC filings for Relay Therapeutics (RLAY), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Relay Therapeutics (RLAY)?

The most recent SEC filing for Relay Therapeutics (RLAY) was filed on November 20, 2026.